Explore /
Poster
/ UCGI 25: A multicentric randomized phase II trial evaluating dual targeting of the epidermal growth factor (EGFR) using the combination of cetuximab and afatinib versus cetuximab alone in patients (pts) wih chemotherapy refractory <span>wtRAS </span>metastatic colorectal cancer (mCRC).

UCGI 25: A multicentric randomized phase II trial evaluating dual targeting of the epidermal growth factor (EGFR) using the combination of cetuximab and afatinib versus cetuximab alone in patients (pts) wih chemotherapy refractory wtRAS metastatic colorectal cancer (mCRC).

Authors

Hélène Senellart

Institut de Cancerologie de l’Ouest-site René Gauducheau, Nantes, France

Hélène Senellart , Emmanuelle Samalin , Antoine Adenis , David Malka , Eric Francois , Christelle De La Fouchardiere , Eveline Boucher , Astrid Lievre , Trevor Stanbury , Jaafar Bennouna

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Clinical Trial Registration Number

NCT01919879

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3666)

DOI

10.1200/jco.2014.32.15_suppl.tps3666

Abstract #

TPS3666

Poster Bd #

120A

Abstract Disclosures

Similar Posters

Poster

2016 ASCO Annual Meeting

$A multi-centric randomized phase II trial evaluating dual targeting of the EGFR with cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS metastatic colorectal cancer (UCGI 25: A UNICANCER trial).$